Abbott settles antitrust allegations over TriCor

Abbott Laboratories stated in a regulatory filing that it intends to pay $184 million to settle class-action claims from pharmacies, wholesalers and generic-drug firms alleging that the company breached antitrust laws by working to block the launch of copies of its cholesterol drug TriCor. Abbott contends that it acted in accordance with the law and agreed to the settlement "to avoid the uncertainty of a trial outcome," a company spokeswoman said.

View Full Article in:

Wall Street Journal, The · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX